Tertatolol does not affect biochemical markers of atherosclerosis in normo- and hyperlipidemic hypertensive patients.
The effects of the beta-blocker tertatolol on plasma lipids and lipoproteins were studied in two groups of 10 normolipidemic (group I) and 10 hyperlipidemic (group II) hypertensive patients, for a period of 3 months. The efficacy of tertatolol was confirmed by a reduction in heart rate (HR), and in systolic (SBP) and diastolic (DBP) blood pressure, in the supine position and after 1 min in the upright position. Triglyceride (TG) levels were increased by treatment in both groups (+20% and +22%, respectively; p less than 0.05), as were VLDL levels (+16% and +24%, respectively) although the rise in the latter was not significant. There were no significant differences in levels of HDL cholesterol (HDL-C), HDL, or apoproteins A and A1 (APO A, APO A1). Total cholesterol (TC) levels were increased by treatment in group I (+10%; p = 0.050) and decreased in group II (-9%, not significant), LDL-C being the principal fraction involved in these changes. There were no significant differences in levels of APO B. The ratio between TC and HDL-C levels remained unchanged. Given the current state of our knowledge concerning lipid markers for atherosclerosis, these results indicate that chronic administration of tertatolol may be considered devoid of 'atherogenic' effects.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D001161:Arteriosclerosis / Q000097:blood*; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006339:Heart Rate; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood*; D006973:Hypertension / Q000097:blood*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000494:pharmacology*; D013876:Thiophenes
D000319:Adrenergic beta-Antagonists; D008055:Lipids; D011412:Propanolamines; D013876:Thiophenes; C005632:tertatolol